Filings under BOLD by Audentes Therapeutics, Inc. (CIK 0001628738) from Jul 25, 2016 to Jan 15, 2020 belong to a different issuer and are not shown.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
| Date | Insider | Role | Action | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 26, 2026 | Tang Kevin | 10% Owner | Sell(S) | 18K | $2.97 | $54K |
| Jul 21, 2026 | Tang Kevin | 10% Owner | Buy(P) | 3K | $2.44 | $7K |
| Jul 20, 2026 | Tang Kevin | 10% Owner | Buy(P) | 2K | $2.44 | $4K |
| Jul 17, 2026 | Tang Kevin | 10% Owner | Buy(P) | 265 | $2.44 | $647 |
| Jul 16, 2026 | Tang Kevin | 10% Owner | Buy(P) | 18K | $2.44 | $45K |
| Jul 15, 2026 | Tang Kevin | 10% Owner | Buy(P) | 2K | $2.44 | $4K |
| Jul 14, 2026 | Tang Kevin | 10% Owner | Buy(P) | 44K | $2.43 | $107K |
| Jul 13, 2026 | Tang Kevin | 10% Owner | Buy(P) | 48K | $2.42 | $117K |
| Jul 10, 2026 | Tang Kevin | 10% Owner | Buy(P) | 43K | $2.43 | $105K |
| Jul 9, 2026 | Tang Kevin | 10% Owner | Buy(P) | 7 | $2.48 | $17 |
| Jul 8, 2026 | Tang Kevin | 10% Owner | Buy(P) | 14K | $2.46 | $35K |
| Jul 7, 2026 | Tang Kevin | 10% Owner | Buy(P) | 16K | $2.48 | $39K |
| Jul 6, 2026 | Tang Kevin | 10% Owner | Buy(P) | 27K | $2.49 | $67K |
| Jul 2, 2026 | Tang Kevin | 10% Owner | Buy(P) | 10K | $2.49 | $24K |
| Jul 1, 2026 | Tang Kevin | 10% Owner | Buy(P) | 72K | $2.49 | $178K |
| Jul 1, 2026 | Crandell Keith | 10% Owner | Option exercise(M) | 16K | $1.03 | $16K |
| Jul 1, 2026 | Crandell Keith | 10% Owner | Sell(S) | 16K | $2.49 | $40K |
| Jul 1, 2026 | Crandell Keith | 10% Owner | Option exercise(M) | 16K | — | $0 |
| Jul 1, 2026 | ARCH Venture Fund IX, L.P. | 10% Owner | Option exercise(M) | 16K | $1.03 | $16K |
| Jul 1, 2026 | ARCH Venture Fund IX, L.P. | 10% Owner | Sell(S) | 16K | $2.49 | $40K |
| Jul 1, 2026 | ARCH Venture Fund IX, L.P. | 10% Owner | Option exercise(M) | 16K | — | $0 |
| Jun 30, 2026 | Tang Kevin | 10% Owner | Buy(P) | 26K | $2.54 | $66K |
| Jun 30, 2026 | Tang Kevin | 10% Owner | Buy(P) | 100 | $2.50 | $250 |
| Jun 29, 2026 | Tang Kevin | 10% Owner | Buy(P) | 64K | $2.47 | $158K |
| Jun 29, 2026 | Tang Kevin | 10% Owner | Buy(P) | 777 | $2.48 | $2K |
| Jun 26, 2026 | Tang Kevin | 10% Owner | Buy(P) | 75K | $2.55 | $191K |
| Jun 26, 2026 | Tang Kevin | 10% Owner | Buy(P) | 134 | $2.54 | $340 |
| Jun 25, 2026 | Tang Kevin | 10% Owner | Buy(P) | 146K | $2.48 | $362K |
| Jun 25, 2026 | Tang Kevin | 10% Owner | Buy(P) | 510 | $2.56 | $1K |
| Jun 15, 2026 | Lew Jennifer | Director | Grant(A) | 32K | — | $0 |
| Jun 15, 2026 | Lim Jonathan E | Director | Grant(A) | 48K | — | $0 |
| Jun 15, 2026 | Christensen James | Director | Grant(A) | 32K | — | $0 |
| Jun 15, 2026 | Whiting Nancy | Director | Grant(A) | 32K | — | $0 |
| Jan 23, 2026 | Hinkle David A | See Remarks | Grant(A) | 140K | — | $0 |
| Jan 23, 2026 | Hornby Zachary | President & CEO, Director | Grant(A) | 600K | — | $0 |
| Jan 23, 2026 | Doebele Robert | Chief Medical Officer | Grant(A) | 230K | — | $0 |
| Jan 23, 2026 | Hassig Christian | Chief Scientific Officer | Grant(A) | 230K | — | $0 |
| Jan 23, 2026 | Oien Jessica | See Remarks | Grant(A) | 220K | — | $0 |
| Jun 23, 2025 | Whiting Nancy | Director | Grant(A) | 16K | — | $0 |
| Jun 23, 2025 | Burow Kristina | Director, 10% Owner | Grant(A) | 16K | — | $0 |
| Jun 23, 2025 | Lim Jonathan E | Director | Grant(A) | 24K | — | $0 |
| Jun 23, 2025 | Lew Jennifer | Director | Grant(A) | 16K | — | $0 |
| Jun 23, 2025 | Christensen James | Director | Grant(A) | 16K | — | $0 |
| Jun 23, 2025 | Brennan Christine | Director | Grant(A) | 16K | — | $0 |
| Feb 3, 2025 | Doebele Robert | Chief Medical Officer | Grant(A) | 180K | — | $0 |
| Jan 22, 2025 | Oien Jessica | See Remarks | Grant(A) | 90K | — | $0 |
| Jan 22, 2025 | Hornby Zachary | President & CEO, Director | Grant(A) | 295K | — | $0 |
| Jan 22, 2025 | Hassig Christian | Chief Scientific Officer | Grant(A) | 95K | — | $0 |
| Jan 22, 2025 | Hinkle David A | See Remarks | Grant(A) | 65K | — | $0 |
| Aug 19, 2024 | Rubin Jami | Chief Financial Officer | Disposed to issuer(D) | 197K | — | — |
| Aug 19, 2024 | Rubin Jami | Chief Financial Officer | Disposed to issuer(D) | 51K | — | — |
| Aug 19, 2024 | Rubin Jami | Chief Financial Officer | Grant(A) | 32K | — | — |
| Aug 19, 2024 | Rubin Jami | Chief Financial Officer | Grant(A) | 197K | — | — |
| Aug 19, 2024 | Rubin Jami | Chief Financial Officer | Grant(A) | 51K | — | — |
| Aug 19, 2024 | Rubin Jami | Chief Financial Officer | Disposed to issuer(D) | 32K | — | — |
| Aug 19, 2024 | Wagner Klaus W. | Chief Medical Officer | Disposed to issuer(D) | 103K | — | — |
| Aug 19, 2024 | Wagner Klaus W. | Chief Medical Officer | Disposed to issuer(D) | 10K | — | — |
| Aug 19, 2024 | Wagner Klaus W. | Chief Medical Officer | Disposed to issuer(D) | 95K | — | — |
| Aug 19, 2024 | Wagner Klaus W. | Chief Medical Officer | Disposed to issuer(D) | 68K | — | — |
| Aug 19, 2024 | Wagner Klaus W. | Chief Medical Officer | Grant(A) | 42K | — | — |
| Aug 19, 2024 | Wagner Klaus W. | Chief Medical Officer | Grant(A) | 103K | — | — |
| Aug 19, 2024 | Wagner Klaus W. | Chief Medical Officer | Grant(A) | 10K | — | — |
| Aug 19, 2024 | Wagner Klaus W. | Chief Medical Officer | Grant(A) | 95K | — | — |
| Aug 19, 2024 | Wagner Klaus W. | Chief Medical Officer | Grant(A) | 68K | — | — |
| Aug 19, 2024 | Wagner Klaus W. | Chief Medical Officer | Disposed to issuer(D) | 42K | — | — |
| Aug 19, 2024 | Abdollahian Neil | Chief Business Officer | Disposed to issuer(D) | 20K | — | — |
| Aug 19, 2024 | Abdollahian Neil | Chief Business Officer | Disposed to issuer(D) | 55K | — | — |
| Aug 19, 2024 | Abdollahian Neil | Chief Business Officer | Disposed to issuer(D) | 37K | — | — |
| Aug 19, 2024 | Abdollahian Neil | Chief Business Officer | Disposed to issuer(D) | 23K | — | — |
| Aug 19, 2024 | Abdollahian Neil | Chief Business Officer | Disposed to issuer(D) | 82K | — | — |
| Aug 19, 2024 | Abdollahian Neil | Chief Business Officer | Grant(A) | 20K | — | — |
| Aug 19, 2024 | Abdollahian Neil | Chief Business Officer | Grant(A) | 55K | — | — |
| Aug 19, 2024 | Abdollahian Neil | Chief Business Officer | Grant(A) | 37K | — | — |
| Aug 19, 2024 | Abdollahian Neil | Chief Business Officer | Grant(A) | 23K | — | — |
| Aug 19, 2024 | Abdollahian Neil | Chief Business Officer | Grant(A) | 82K | — | — |
| Aug 19, 2024 | Hornby Zachary | President & CEO, Director | Grant(A) | 162K | — | — |
| Aug 19, 2024 | Hornby Zachary | President & CEO, Director | Grant(A) | 257K | — | — |
| Aug 19, 2024 | Hornby Zachary | President & CEO, Director | Grant(A) | 471K | — | — |
| Aug 19, 2024 | Hornby Zachary | President & CEO, Director | Grant(A) | 256K | — | — |
| Aug 19, 2024 | Hornby Zachary | President & CEO, Director | Disposed to issuer(D) | 162K | — | — |
| Aug 19, 2024 | Hornby Zachary | President & CEO, Director | Disposed to issuer(D) | 257K | — | — |
| Aug 19, 2024 | Hornby Zachary | President & CEO, Director | Disposed to issuer(D) | 471K | — | — |
| Aug 19, 2024 | Hornby Zachary | President & CEO, Director | Disposed to issuer(D) | 256K | — | — |
| Aug 19, 2024 | Oien Jessica | See Remarks | Grant(A) | 26K | — | — |
| Aug 19, 2024 | Oien Jessica | See Remarks | Grant(A) | 42K | — | — |
| Aug 19, 2024 | Oien Jessica | See Remarks | Grant(A) | 10K | — | — |
| Aug 19, 2024 | Oien Jessica | See Remarks | Disposed to issuer(D) | 10K | — | — |
| Aug 19, 2024 | Oien Jessica | See Remarks | Grant(A) | 32K | — | — |
| Aug 19, 2024 | Oien Jessica | See Remarks | Grant(A) | 29K | — | — |
| Aug 19, 2024 | Oien Jessica | See Remarks | Disposed to issuer(D) | 42K | — | — |
| Aug 19, 2024 | Oien Jessica | See Remarks | Disposed to issuer(D) | 36K | — | — |
| Aug 19, 2024 | Oien Jessica | See Remarks | Disposed to issuer(D) | 26K | — | — |
| Aug 19, 2024 | Oien Jessica | See Remarks | Disposed to issuer(D) | 29K | — | — |
| Aug 19, 2024 | Oien Jessica | See Remarks | Disposed to issuer(D) | 32K | — | — |
| Aug 19, 2024 | Oien Jessica | See Remarks | Grant(A) | 16K | — | — |
| Aug 19, 2024 | Oien Jessica | See Remarks | Grant(A) | 36K | — | — |
| Aug 19, 2024 | Oien Jessica | See Remarks | Disposed to issuer(D) | 16K | — | — |
| Aug 19, 2024 | Hassig Christian | Chief Scientific Officer | Grant(A) | 10K | — | — |
| Aug 19, 2024 | Hassig Christian | Chief Scientific Officer | Grant(A) | 63K | — | — |
| Aug 19, 2024 | Hassig Christian | Chief Scientific Officer | Disposed to issuer(D) | 10K | — | — |
Insider transactions sourced from SEC EDGAR Form 4 filings, normalized within minutes of acceptance. "Buy"/"Sell" mark open-market transactions (codes P/S), the tradeable signal. Awards, option exercises and tax-withholding are shown with their raw code. All data is public domain.
Issuer: Boundless Bio, Inc., SEC CIK 0001782303. The symbol on a Form 4 is typed by the filer, so this page follows the issuer with the newest filing under BOLD and shows every filing by that issuer. Earlier filings under the same symbol by another issuer are left out.
Coverage: Form 4 filings indexed 2006-01-02 → 2026-09-05. Earlier history is backfilling; this window widens as it deepens.
Programmatic access via the Arkolith API & MCP server (insider.transactions, insider.company).
Connected pages for BOLD